Needham & Company LLC Forecasts Strong Price Appreciation for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target increased by research analysts at Needham & Company LLC from $20.00 to $25.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 37.36% from the stock’s current price.

Several other research firms have also issued reports on MLTX. Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 29th. BTIG Research increased their price target on shares of MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the company a “buy” rating in a report on Monday. Royal Bank Of Canada boosted their price objective on shares of MoonLake Immunotherapeutics from $10.00 to $12.00 and gave the stock a “sector perform” rating in a report on Friday, February 20th. The Goldman Sachs Group downgraded MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and upped their price target for the company from $8.00 to $10.00 in a report on Wednesday, January 14th. Finally, UBS Group set a $24.00 price objective on MoonLake Immunotherapeutics in a report on Friday, January 9th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, MoonLake Immunotherapeutics has a consensus rating of “Hold” and a consensus price target of $27.15.

MoonLake Immunotherapeutics Stock Performance

MoonLake Immunotherapeutics stock opened at $18.20 on Monday. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $1.17 billion, a P/E ratio of -5.48 and a beta of 1.21. The stock’s 50 day moving average is $15.38 and its 200 day moving average is $23.61.

Insiders Place Their Bets

In other news, insider Kristian Reich sold 72,908 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $14.43, for a total value of $1,052,062.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Da Silva Jorge Santos sold 70,000 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the sale, the chief executive officer owned 2,878,577 shares in the company, valued at $41,710,580.73. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 402,908 shares of company stock valued at $5,987,162. Corporate insiders own 12.05% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC bought a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter worth about $26,000. FNY Investment Advisers LLC bought a new position in MoonLake Immunotherapeutics during the third quarter valued at approximately $28,000. Bank of America Corp DE grew its holdings in MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after buying an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after acquiring an additional 3,166 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after buying an additional 1,069 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.

Key Stories Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Strong phase‑2 efficacy drove investor enthusiasm — sonelokimab showed high response rates in axSpA/chronic back‑pain programs (reported ~81% ASAS40 at Week 12) and S‑OLARIS data were highlighted at Investor Day, supporting the drug’s multi‑indication potential. MoonLake stock surges on positive axSpA trial data
• Positive Sentiment: Separate reports emphasize Phase‑2 chronic back pain success, which helped pre‑market gains and bolstered confidence into Investor Day. MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
• Neutral Sentiment: Multiple analysts raised price targets and kept buy ratings (BTIG to $30, Needham to $25; other outlets reported increases), reflecting upside expectations if late‑stage programs progress. Benzinga analyst coverage
• Neutral Sentiment: Company released Investor Day materials (slides and transcript) and highlighted S‑OLARIS updates and program priorities — useful for modeling but not immediately dilutive. MoonLake Analyst/Investor Day – Slideshow
• Neutral Sentiment: Quarterly results showed EPS of ($0.97), in line with consensus but still a cash‑burning profile; that met expectations but leaves funding and profitability questions for longer‑term holders. Earnings press release
• Negative Sentiment: Mixed phase‑3 hidradenitis suppurativa (HS) readouts: VELA‑2 missed its primary endpoint, prompting at least one downgrade (Strong Buy → Buy). Although the FDA Type B meeting leaves a pathway to file a BLA using pooled data, the VELA‑2 miss increases regulatory and commercial execution risk. MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.